NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Clinical trials for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NON-SQUAMOUS NON-SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NON-SQUAMOUS NON-SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug shows promise for Gene-Driven lung cancers
Disease control CompletedThis phase 2 trial tests the drug crizotinib (XALKORI) in people with advanced non-small cell lung cancer that has spread and carries a change in the ROS1 or MET gene. Participants take crizotinib by mouth twice daily. The study aims to see how well the drug shrinks tumors and de…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immunotherapy combo shows promise in advanced lung cancer trial
Disease control CompletedThis phase 3 study tested whether adding the immunotherapy drug sintilimab to standard chemotherapy helps people with advanced non-squamous non-small cell lung cancer. 397 participants received either sintilimab plus chemo or a placebo plus chemo. The main goal was to see if the …
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug, TAK-981, combined with the immunotherapy pembrolizumab in 161 adults with advanced or metastatic solid tumors that could not be cured. The main goals were to check safety and see if the combination could shrink tumors. Participants received treatment…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug duo shows promise in shrinking tough cancers
Disease control CompletedThis study tested a combination of two experimental drugs (BI 836880 and ezabenlimab) in 252 adults with advanced non-squamous lung cancer and other solid tumors. The first part found the safest dose; the second part checked if the combo could shrink tumors. Participants received…
Matched conditions: NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC